Am J Psychiatry 158:765-774, May 2001
© 2001 American Psychiatric Association
A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder
Robert R. Conley, M.D., and
Ramy Mahmoud, M.D., M.P.H.
OBJECTIVE: The safety and efficacy of risperidone and olanzapine were compared in a double-blind trial that used doses widely accepted in clinical practice. METHOD: Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2–6 mg/day of risperidone (mean modal dose=4.8 mg/day) or 5–20 mg/day of olanzapine (mean modal dose=12.4 mg/day) for 8 weeks. RESULTS: The two study groups were similar at baseline except that the olanzapine group was slightly younger than the risperidone group. Seventy-five percent of the participants completed the trial, with no between-treatment differences in the proportion of dropouts. Similar proportions of the risperidone and olanzapine groups reported extrapyramidal symptoms (24% and 20%, respectively). Severity of extrapyramidal symptoms was low in both groups, with no between-group differences. Total Positive and Negative Syndrome Scale scores and scores on the five Positive and Negative Syndrome Scale factors were improved in both groups at week 8 (subjects who completed the study) and endpoint (all subjects, including dropouts). There were overall between-treatment differences in efficacy. Comparison of individual factors found no significant differences at endpoint; at week 8, however, improvements on Positive and Negative Syndrome Scale factors for positive symptoms and anxiety/depression were greater with risperidone than olanzapine. An increase in body weight of  7% was seen in 27% of olanzapine participants and 12% of risperidone participants. CONCLUSIONS: Both treatments were well tolerated and efficacious. The frequency and severity of extrapyramidal symptoms were similar in the two treatment groups. Greater reductions in severity of positive and affective symptoms were seen with risperidone than with olanzapine treatment among study completers. There was no measure on which olanzapine was superior. Greater weight gain was associated with olanzapine than with risperidone treatment.
This article has been cited by other articles:
|
|
|
|
 
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull,
February 26, 2008;
(2008)
sbn005v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rabinowitz and O. Davidov
A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications
Schizophr Bull,
September 29, 2007;
(2007)
sbm107v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. KEKS, M. INGHAM, A. KHAN, and K. KARCHER
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study
The British Journal of Psychiatry,
August 1, 2007;
191(2):
131 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Robinson, M. G. Woerner, B. Napolitano, R. C. Patel, S. M. Sevy, H. Gunduz-Bruce, J. M. Soto-Perello, A. Mendelowitz, A. Khadivi, R. Miller, et al.
Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes
Am J Psychiatry,
December 1, 2006;
163(12):
2096 - 2102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
6 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. E. McCUE, R. WAHEED, L. URCUYO, G. ORENDAIN, M. D. JOSEPH, R. CHARLES, and S. M. HASAN
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
The British Journal of Psychiatry,
November 1, 2006;
189(5):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. TANDON
Comparing Antipsychotic Efficacy
Am J Psychiatry,
September 1, 2006;
163(9):
1645 - 1645.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
Am J Psychiatry,
February 1, 2006;
163(2):
185 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker
Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis
Arch Gen Psychiatry,
December 1, 2005;
62(12):
1305 - 1312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Haddad
Weight change with atypical antipsychotics in the treatment of schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
16 - 27.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Breier, P. H. Berg, J. H. Thakore, D. Naber, W. F. Gattaz, P. Cavazzoni, D. J. Walker, S. M. Roychowdhury, and J. M. Kane
Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia
Am J Psychiatry,
October 1, 2005;
162(10):
1879 - 1887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Liperoti, G. Gambassi, K. L. Lapane, C. Chiang, C. Pedone, V. Mor, and R. Bernabei
Conventional and Atypical Antipsychotics and the Risk of Hospitalization for Ventricular Arrhythmias or Cardiac Arrest
Arch Intern Med,
March 28, 2005;
165(6):
696 - 701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Simpson, I. D. Glick, P. J. Weiden, S. J. Romano, and C. O. Siu
Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder
Am J Psychiatry,
October 1, 2004;
161(10):
1837 - 1847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A Sprague, P. S Loewen, and C. B Raymond
Selection of Atypical Antipsychotics for the Management of Schizophrenia
Ann. Pharmacother.,
February 1, 2004;
38(2):
313 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G Liu, S. X Sun, D. B Christensen, and X. Luo
Cost Comparisons of Olanzapine and Risperidone in Treating Schizophrenia
Ann. Pharmacother.,
January 1, 2004;
38(1):
134 - 141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Agid, S. Kapur, T. Arenovich, and R. B. Zipursky
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Arch Gen Psychiatry,
December 1, 2003;
60(12):
1228 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, T. R.E. Barnes, W. Kissling, R. R. Engel, C. Correll, and J. M. Kane
Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials
Am J Psychiatry,
July 1, 2003;
160(7):
1209 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry,
June 1, 2003;
60(6):
553 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Byerly, M. Weber, D. Brooks, S. B. Casey, S. Elliot, and J. Hawkins
Cost Evaluation of Risperidone Compared With Olanzapine
Psychiatr Serv,
May 1, 2003;
54(5):
742 - 744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Santarlasci and A. Messori
Clinical Trial Response and Dropout Rates with Olanzapine Versus Risperidone
Ann. Pharmacother.,
April 1, 2003;
37(4):
556 - 563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. OSSER and A. AKHTER
Comparative Effectiveness of Antipsychotic Drugs
Am J Psychiatry,
March 1, 2003;
160(3):
590 - 590.
[Full Text]
|
|
|
|
|
|
|
G. Nicholson, A. C. Pereira, and G. M. Hall
Parkinson's disease and anaesthesia
Br. J. Anaesth.,
December 1, 2002;
89(6):
904 - 916.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
